Disentangling the mutational effects on protein stability and interaction of human MLH1

Sven Larsen-Ledet[1] and Amelie Stein[1,*]

Running title: Characterizing mechanistic effects of MLH1 variants

Keywords: protein abundance; protein-protein interaction; multiplexed assays of variant effects; MAVE; ClinVar; variant interpretation; Lynch syndrome

1: Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen, Denmark.

*: to whom correspondence should be addressed amelie.stein@bio.ku.dk

Abstract

Missense mutations can have diverse effects on proteins, depending on their location within the protein and the specific amino acid substitution. Mutations in the DNA mismatch repair gene *MLH1* are associated with Lynch syndrome, yet the underlying mechanism of most disease-causing mutations remain elusive. To address this gap, we aim to disentangle the mutational effects on two essential properties for MLH1 function: protein stability and protein-protein interaction. We systematically examine the cellular abundance and interaction with PMS2 of 4839 (94%) MLH1 variants in the C-terminal domain. Our combined data shows that most MLH1 variants lose interaction with PMS2 due to reduced cellular abundance. However, substitutions to charged residues in the canonical interface lead to reduced interaction with PMS2. Unexpectedly, we also identify a distal region in the C-terminal domain of MLH1 where substitutions cause both decreased and increased binding with PMS2. Our data successfully distinguish benign from pathogenic MLH1 variants and correlate with thermodynamic stability predictions and evolutionary conservation. This work provides mechanistic insights into variant consequences and may help interpret MLH1 variants.

Introduction

Proteins constitute the functional units of the cell and perform essential cellular processes to sustain cell function and health. To obtain biological function, most proteins must fold into a marginally stable native structure, which is largely determined by the amino acid sequence [1]. This makes proteins extremely sensitive to missense mutations that disrupt the structural stability which leads to protein degradation and reduced cellular abundance. Thus, protein stability is fundamental for protein function and, indeed, the most frequent mechanism of disease-causing missense mutations is through destabilization and degradation [2–9]. However, in addition to protein stability, proteins often have other properties that are important for their function. The function of most proteins relies on interactions with other proteins to form complexes and networks, making protein-protein interactions (PPIs) a central property of protein function [10–12].

In general, PPIs can be grouped into obligate or non-obligate interactions based on whether the proteins function only as a complex or can also function as monomers [13,14]. Non-obligate interactions are often of lower affinity, transient, and involved in regulatory and signaling pathways, whereas obligate PPIs are typically stronger with larger and more hydrophobic interfaces [15–17]. Several studies have shown that disease-causing missense mutations are enriched in PPI interfaces [18–21], and it has been estimated that the underlying mechanism of around half of all disease-causing missense mutations in proteins that interact with other proteins is through the perturbation of specific interfaces [22–24]. This suggests that numerous clinically relevant protein variants affecting PPI interfaces remain stable in the cell, which highlights that mutations may affect protein stability and PPIs differently, depending on the type and site of the mutation. Mechanistic insights into mutational effects on protein stability and interactions have important implications for our understanding of protein function and diseases, and may provide avenues towards developing treatments.

MutL homolog 1 (MLH1) is a 756-residue protein that folds into an N- and a C-terminal domain, separated by a long intrinsically disordered linker [25]. MLH1 forms an obligate heterodimer with postmeiotic segregation increased 2 (PMS2), termed MutLα. Although the structure of the human MutLα complex remains unresolved, it is known that MLH1 and PMS2 dimerize through their C-terminal domains [26]. MutLα participates in the conserved DNA mismatch repair (MMR) pathway that detects and repairs base-base mismatches during DNA replication [27,28]. Defects in the MMR pathway increase the risk of spontaneous somatic mutations and sporadic cancers. Loss of function mutations in MLH1 cause Lynch syndrome, an inherited disease that predisposes individuals to various cancer types, such as colorectal and

endometrial cancer [29,30]. A large proportion of Lynch syndrome patients suffer from pathogenic missense mutations in the *MLH1* gene [31,32]. However, the mechanistic effects of most of these variants are still unknown, and most of the MLH1 variants observed in the population are still categorized as variants of uncertain significance (VUS) [33–35].

Here, we use orthogonal yeast-based growth assays to disentangle the mutational effects on the abundance of MLH1 and on its interaction with PMS2. We systematically screen site-saturated libraries comprising 4839 (94%) missense and nonsense variants in the C-terminal domain of human MLH1. We find that MLH1 variants predominantly affect protein abundance compared to interaction and that these positions often are confined to buried residues. However, substitutions to charged residues in positions in the suggested interface between MLH1 and PMS2 are detrimental to interaction. Surprisingly, we find that a region distal to the interface confers improved interaction without affecting abundance. We find that the experimental results correlate with computational predictions and can distinguish clinically classified pathogenic variants from benign population variants. Our data suggest that single missense mutations are more likely to affect abundance than interaction but do pinpoint specific positions critical for interaction in known and novel interfaces with PMS2.

Results

Yeast-based assays to measure MLH1 abundance and interaction with PMS2

To disentangle the mutational effects on protein abundance and interaction, we selected the interaction between the human proteins MLH1 and PMS2. MLH1 and PMS2 form the MutLα complex through their C-terminal domains, an essential component of the DNA mismatch repair pathway (**Fig. 1A**). The structure of the human C-terminal MutLα complex is unknown, and the C-terminal domain of PMS2 has not been structurally resolved, making it challenging to accurately assign the interface between the two proteins. However, the human proteins show sequence (57%) and structural similarity with their yeast orthologs, MLH1 and PMS1, suggesting that the human complex may be similar to the structure of the yeast complex (PDB: 4EW4) [36]. We used AlphaFold2-Multimer to model the human C-terminal MutLα complex (**Fig. 1A**, **Supplementary Fig. 1**). The structure predicted that MLH1 and PMS2 dimerize through four β-strands, three of which are close in sequence, while the fourth is located towards the C-terminus.

To measure the abundance of MLH1 variants, we used a previously described dihydrofolate reductase protein-fragment complementation assay (DHFR-PCA) (**Fig. 1B**) [37–40]. This assay is based on a methotrexate-resistant variant of murine DHFR, which is split into two fragments, F[1,2] and F[3], that are expressed separately but from the same centromere-based vector in wild-type *S. cerevisiae* cells (**Supplementary Fig. 2**). The F[3] is fused to MLH1, while the F[1,2] remains free (untagged). Plating of cells on medium with methotrexate (MTX) inhibits the essential endogenous yeast Dfr1 and makes growth dependent on reconstitution of the methotrexate-resistant variant of murine DHFR. A stable, high-abundant MLH1 variant enables reconstitution, allowing growth in the presence of MTX, whereas an unstable, low-abundance MLH1 variant prevents reconstitution, resulting in reduced growth in the presence of MTX. Hence, the DHFR-PCA couples cellular abundance of MLH1 to yeast growth. However, this assay solely measures the abundance of MLH1 variants and hence is not amenable to report on other properties important to MLH1 function, such as its interaction with PMS2. Therefore, we used the yeast two-hybrid (Y2H) assay to assess the binding of MLH1 variants to PMS2 (**Fig. 1C**) [41]. In this assay, MLH1 and PMS2 are fused to the activation domain (AD) and DNA binding domain (DBD) of the GAL4 transcription factor, respectively. The two fusion proteins are expressed from their own centromere-based vectors in the MaV203 yeast strain (**Supplementary Fig. 3A**, **Supplementary Fig. 3B**). If MLH1 and PMS2 interact, the AD and DBD reconstitute the Gal4 transcription factor and initiate the expression of the *HIS3* reporter gene, enabling growth on medium without histidine.

In order to examine the sensitivity and dynamic range of the DHFR-PCA and Y2H assay, we performed small-scale yeast growth assays of the wild-type and five MLH1 variants (**Fig. 2A**). The Q542L and L550P variants locate to the C-terminal domain of MLH1, the S406N variant locates to the intrinsically disordered linker and the I219V and T117M variants locate to the N-terminal domain of MLH1. The S406N and I219V variants are classified as benign in the ClinVar database [42] and frequently observed in the population, as reported in the Genome Aggregation Database (gnomAD) [43]. The L550P and T117M variants are known to cause Lynch syndrome, are classified as pathogenic, and are extremely rare in the population. The Q542L variant is classified as VUS, but it has previously been shown to display wild-type-like abundance, interaction with PMS2, and MMR activity [32,44–46]. In both assays, the empty vector displayed a strong growth defect in the presence of MTX and absence of histidine, respectively, compared to the wild-type (**Fig. 2A**). The Q542L, S406N, and I219V variants showed similar growth to the wild-type, whereas the L550P and T117M variants exhibited a similar growth defect to the empty vector (**Fig. 2A**). This suggests that the L550P and T117M variants likely lose PMS2 interaction due to reduced cellular abundance. In conclusion, this data confirmed that the DHFR-PCA and Y2H assay could report on MLH1 abundance and its interaction with PMS2, respectively, and distinguish benign population variants from clinically pathogenic ones.

Saturated abundance and interaction maps of MLH1 variants

Next, we used the DHFR-PCA and Y2H assay to determine the abundance and PMS2 interaction of all possible missense variants in the C-terminal domain (position 487-756) of human MLH1 (**Fig. 2B**). We decided to focus only on the C-terminal domain of MLH1, as it mediates the interaction with PMS2, and we expected variants in the N-terminal domain to have little impact on this interaction. We divided the C-terminal domain into seven tiles (**Supplementary Fig. 4A**) and designed site-saturation mutagenesis libraries in each tile, which were synthesized and cloned into a Gateway-compatible vector to produce the entry libraries. The entry libraries were cloned into destination vectors tailored to the DHFR-PCA and Y2H assay, respectively, and subsequently transformed into appropriate yeast strains. The transformation cultures were grown until saturation and then cells were plated in triplicates onto control and selection medium, and incubated at 30 °C. In the DHFR-PCA, cells were grown on medium with MTX to select for MLH1 abundance, and in the Y2H assay, cells were grown on medium without histidine to select for PMS2 interaction. Following incubation, cells were scraped off the plates and directly used for plasmid isolation and amplicon preparation.

The amplicons were sequenced using paired-end next-generation sequencing and the resulting sequencing data was analyzed using Enrich2 [47] to calculate an abundance score and a PMS2 interaction score for each MLH1 variant (**Fig. 2B**). The variant scores were calculated by comparing the change in frequency of each variant to that of synonymous wild-type variants in both the control and selection conditions. The MLH1 abundance scores displayed a bimodal distribution with many variants centered around 0 (wild-type-like) and a peak of low-abundance variants with negative scores (**Supplementary Fig. 4B**). However, due to the observed variance in negative scores across tiles within the low-abundance peak (**Supplementary Fig. 4B**) we rescaled the abundance scores to range from -1 to 1 (**Fig. 2C**), which standardized the abundance scores and ensured uniformity across tiles. The distribution of interaction scores largely appeared centered around 0 (wild-type-like) with some variants showing reduced interaction with negative interaction scores, while a few variants exhibited improved interaction with positive interaction scores (**Fig. 2C**, **Supplementary Fig. 4C**). The interaction scores were not rescaled. As expected, the L550P variant displayed reduced abundance and interaction, in line with the results from the small-scale yeast growth assays and underscoring the validity of the high-throughput screens (**Fig. 2A**, **Fig. 2C**).

The abundance and interaction datasets contained variant effects for 4839 (94%) out of 5170 (19 substitutions/position*270 residues + 40 nonsense mutations) possible programmed MLH1 variants in the C-terminal domain. The abundance and interaction scores showed high correlation between the three replicates, but the DHFR-PCA had relatively lower correlations compared to the Y2H assay (minimum R=0.92 vs. minimum R=0.96) (**Supplementary Fig. 5**, **Supplementary Fig. 6**). Overall, substitutions in the C-terminal domain of MLH1 more often conferred reduced abundance than affecting the interaction with PMS2 (**Fig. 3A**, **Fig. 3C**). The abundance map revealed that substitutions were detrimental in several positions and particularly in secondary structural elements (**Fig. 3A**). The internal loop spanning position 591-605, as well as some positions close to the N- and C-termini were tolerant to substitutions (**Fig. 3A**). As expected, the disordered region with low AlphaFold2-Multimer-predicted pLDDT scores at position 692-711 was insensitive to substitutions, whereas substitutions to proline appeared detrimental to abundance, and to a lesser extent to interaction, at most positions (**Fig. 3**). Interestingly, nonsense mutations caused reduced abundance and interaction up until position 742, but from position 745-756, stop codon variants displayed increased abundance compared to the wild-type (**Fig. 3**). Additionally, several point mutations at positions toward the C-terminus led to increased abundance and interaction (**Fig. 3**). We mapped the median abundance scores onto the C-terminal domain of MLH1 in the AlphaFold2-

Multimer-predicted structure of the human C-terminal MutLα complex (**Fig. 3B**). This revealed that most of the sensitive positions were pointing inwards, while exposed and flexible positions were tolerant to substitutions. Indeed, the median abundance scores correlated with relative solvent accessible surface area (rSASA), and indicated that substitutions in buried, core positions were more detrimental than in surface-exposed positions (**Supplementary Fig. 7A**). The interaction map revealed that the impact of MLH1 variants on the interaction with PMS2 was confined to specific positions rather than being widespread (**Fig. 3C**). In general, most variants that displayed reduced interaction with PMS2 also appeared low-abundant, suggesting that loss of stability was the primary mechanism of reduced interaction with PMS2 (**Fig. 3A**, **Fig. 3C**). In line with this, we observed that low median interaction scores were only observed for buried positions (**Supplementary Fig. 7B**). Large regions at the beginning and end of the C-terminal domain of MLH1 were completely tolerant to substitutions, with most variants exhibiting wild-type-like interaction with PMS2 (**Fig. 3C**). It was evident that substitutions from hydrophobic wild-type residues to both negatively and positively charged amino acids in the β-strands constituting the canonical interface at position 539-541 and 547-550 were detrimental to the interaction (**Fig. 3C**). Interestingly, at position 540, the substitution to glutamic acid had no effect on the interaction with PMS2, whereas the substitution to aspartic acid displayed complete loss-of-interaction (**Fig. 3C**). We noticed that the introduction of tryptophan at position 544, which is located in the short loop between the second and third β-strand of the canonical interface, substantially improved the binding with PMS2 (**Fig. 3C**). In addition, MLH1 variants immediately upstream of the central α-helix, specifically at position 601-604, showed increased binding with PMS2 (**Fig. 3C**). This effect was most pronounced for substitutions to hydrophobic or aromatic residues and disappeared with substitutions to charged residues (**Fig. 3C**). To validate the effects on PMS2 interaction observed in this screen, we performed low-throughput Y2H growth assays on four loss-of-interaction variants and three gain-of-interaction variants (**Supplementary Fig. 8**).

To visualize the variant effects on PMS2 interaction, we mapped the median interaction scores onto MLH1 in the predicted C-terminal MutLα complex (**Fig. 3D**). The mapping revealed that substitutions of surface-exposed residues in the central α-helix spanning position 605-627 exhibited slightly decreased interaction with PMS2, without affecting the MLH1 abundance (**Fig. 3B**, **Fig. 3D**). This led us to speculate that MLH1 and PMS2 interact through an additional interface, distal to the canonical four β-strands known from the yeast complex [36] (**Supplementary Fig. 9**). Indeed, PMS2 was predicted to harbor an α-helix (position 622-639) extending towards another region in MLH1 that was not particularly close to the central α-helix

(**Fig. 3D**). However, we noticed that the linker region preceding the α-helix in PMS2 was predicted with low confidence in the C-terminal MutLα complex by AlphaFold2-Multimer (**Supplementary Fig. 10A**). This suggests that the α-helix might have been placed incorrectly. It might instead bind directly to the central α-helix in MLH1, where we observed both loss- and gain-of-interaction variants. To further investigate this possibility, we predicted the structure of the C-terminal domain of MLH1 in complex with the fragment corresponding to the α-helix in PMS2. The AlphaFold2-Multimer model placed the PMS2 α-helix as interacting with the central α-helix in MLH1 (**Supplementary Fig. 10B**). The mapping of the median interaction scores to the structure also revealed that several positions in the helices neighboring the central α-helix were highly sensitive to substitutions (**Fig. 3D**). However, these residues pointed inward, and substitutions resulted in reduced abundance, suggesting that the loss of interaction was likely due to decreased stability (**Fig. 3B**, **Fig. 3D**).

Computational predictions and clinical data correlate with variant effects

The above data indicate that MLH1 abundance and its interaction with PMS2 are tightly connected and loss of interaction is often caused by loss of stability. To further examine this relationship, we used predictive computational tools to evaluate the impact of MLH1 variants on thermodynamic folding stability and their likelihood of being tolerated based on the evolutionary history. We used Rosetta [48] to predict the changes in thermodynamic stability (ΔΔG) of all possible missense variants in the C-terminal domain of MLH1. However, in addition to stability, certain residues may be important for other aspects of MLH1 function, such as its interaction with PMS2. Such residues are often conserved across species, and therefore analysis of homologous sequences can report on the mutational tolerance at these positions. To this end, we used GEMME [49] to model the evolutionary history of MLH1 sequences and then predict the required adaptation of the MLH1 sequence to accommodate all possible missense variants in the C-terminal domain of MLH1. GEMME returned a ΔΔE score for each MLH1 variant, ranging from 0 (tolerated substitution) to –6 (non-tolerated substitution based on evolutionary conservation). Rosetta and GEMME separated the MLH1 variants according to their predicted effects on MLH1 stability and other properties important for function, respectively (**Fig. 4A**). We observed that the majority of variants were predicted to have a ΔΔG score below 2 and ΔΔE score above –2, suggesting that they exhibited similar stability and functional properties as the wild-type (**Fig. 4A**). Several variants were predicted to be incompatible with MLH1 function (strongly negative ΔΔE scores) and some of them were also predicted to be unstable (positive ΔΔG score) (**Fig. 4A**). We mapped the experimental

abundance scores to the predictions, which revealed that variants with wild-type-like abundance clustered in the upper left corner, whereas low-abundant MLH1 variants mapped towards the bottom right corner (**Fig. 4A**). An analogous pattern appeared when we mapped the experimental interaction scores to the predictions (**Fig. 4B**). This indicates that most of the loss-of-interaction variants were predicted to be detrimental based on the evolutionary history while also losing structural stability, confirming the close relationship between MLH1 abundance and its interaction with PMS2.

To assess the clinical relevance of the generated datasets, we next compared the experimental abundance and interaction scores with the clinical classifications in the ClinVar database [42] and population allele frequencies of known MLH1 variants that have been reported in gnomAD [43] (**Fig. 4C**, **Fig. 4D**). This showed that variants that are common in the human population tended to behave like the wild-type, whereas several of the rare population MLH1 variants displayed reduced abundance and interaction with PMS2. To evaluate if our abundance and interaction scores could differentiate harmless benign variants from disease-associated pathogenic variants, we colored the MLH1 variants based on their classification in ClinVar [42] (**Fig. 4C**, **Fig. 4D**). The five pathogenic MLH1 variants were extremely rare in the population, and all displayed much reduced abundance (**Fig. 4C**). Conversely, most of the benign and likely benign MLH1 variants were frequently found among individuals and exhibited wild-type-like protein levels (**Fig. 4C**). Additionally, several rare VUS exhibited similarly low abundance levels as the pathogenic variants, indicating that these variants are likely to be disease-causing (**Fig. 4C**). The K618T variant had an abundance score of –1, despite being classified as benign (**Fig. 4C**). This variant has previously been shown to have reduced cellular abundance, nuclear localization and MMR activity [46,50–53], while other studies have suggested this variant to form a stable protein [32]. Thus, despite the variant being too frequent in the population to be a fully penetrant Lynch syndrome variant, its clinical interpretation remains inconclusive [54]. The interaction scores were also able to distinguish most benign from pathogenic variants (**Fig. 4D**). The pathogenic R687T variant showed wild-type-like interaction with PMS2 but dramatically decreased abundance, suggesting that the disease-mechanism of this variant is through loss of stability (**Fig. 4C**, **Fig. 4D**). Interestingly, some of the MLH1 variants that displayed improved interaction with PMS2 were classified as VUS but were extremely rare in the population (**Fig. 4D**). This could suggest that these variants are pathogenic, and thus gain of interaction may represent an additional underlying disease-mechanism of Lynch syndrome.

Discussion

Most proteins have several properties that contribute to their function. Here, we have combined two multiplexed assays of variant effects (MAVEs), one probing stability and another probing interaction, to disentangle which variants affect either or both properties in the C-terminal domain of human MLH1.

Loss-of-function mutations in the *MLH1* gene lead to Lynch syndrome, a cancer predisposing disease. Loss of stability has been shown to be a common mechanism of loss-of-function phenotypes [3,33,55–57], and pathogenic variants are shown to be enriched in interaction interfaces [18–21]. Our data helps pinpoint whether the molecular mechanism underlying pathogenicity of a given variant is loss of stability, loss of interaction with PMS2, or yet other properties of the protein. Our results indicate that several mutations reduce protein stability, while far fewer variants affect the interaction. At the same time, variants that result in a loss of interaction often display reduced abundance levels. These observations suggest that it is difficult to perturb the interaction with PMS2 without also compromising the structure of the MLH1 protein. We envision that this intricate relationship between structural protein stability and protein-protein interactions (PPIs) reflects the nature of structured interfaces, such as the interaction between MLH1 and PMS2. Thus, for single MLH1 missense mutations to affect the interaction with PMS2, it requires strong effects that are unlikely to occur without also structurally affecting MLH1 stability. This contrasts with PPIs mediated through smaller interfaces and involving unstructured components, such as short linear motifs in intrinsically disordered regions [58,59]. In those cases, missense mutations are expected to have local effects on specific binding sites rather than globally perturbing protein stability.

Despite the difficulty in disentangling protein stability and PMS2 interaction for MLH1 variants, we observe that substitutions to charged residues in two of the four β-strands constituting the canonical interface with PMS2 are detrimental to the interaction. We note that this interface is enriched with hydrophobic residues and completely depleted of charged residues, which may explain why the introduction of charged residues in these β-strands is unfavorable for the interaction with PMS2 (**Supplementary Fig. 11**) [60]. Interestingly, at position 540, only substitutions to aspartic acid and arginine are detrimental, whereas substitutions to glutamic acid and lysine exhibit wild-type-like interaction. This suggests that charge is not the only determinant of the effect on PMS2 interaction; spatial constraints and the local environment of the interface also influence the effect of substitutions. In addition to the canonical interface, substitutions within and immediately before a central α-helix of MLH1 lead to reduced and increased binding with PMS2, respectively. This effect is presumed to

occur via an α-helix that extends towards the disordered linker region of PMS2. We hypothesize that this is a novel interaction site between MLH1 and PMS2.

Counterintuitively, some MLH1 variants that appear unstable still exhibit wild-type-like interaction with PMS2. We confirm this observation for selected variants in low-throughput (**Supplementary Fig. 12A**, **Supplementary Fig. 12B**). This suggests differences in the dynamic range and sensitivity of the DHFR-PCA and Y2H assay. We believe there are several possible explanations for this. First, the expression of the *HIS3* gene in the Y2H assay likely provides a much more sensitive read-out compared to the reconstitution of the murine DHFR in the DHFR-PCA. This sensitivity difference could potentially be mitigated by using a higher concentration of 3-AT to increase the selection pressure on the interaction, thereby shifting the dynamic range to select for variants that mildly affect the interaction without perturbing the protein stability. Second, it has been shown that the DHFR-PCA underestimates the abundance of proteins localized to subcellular compartments (e.g., the nucleus), as the binding of the F[1,2] and F[3] fragments of murine DHFR occurs in the cytosol [39]. However, studies have shown that translocation of MLH1 into the nucleus depends on its heterodimerization with PMS2 [61–64]. Since the DHFR-PCA is performed without co-expression of PMS2, a large fraction of MLH1 is expected to be present in the cytosol. We hypothesize that this ectopic cytosolic localization and absence of PMS2 negatively affect MLH1 stability.

Our abundance and interaction maps reveal that removal of residues 745-756 of MLH1 leads to both enhanced stability and interaction with PMS2. We find it unlikely that this effect is due to a decrease in degron potency, as this region is not enriched with hydrophobic residues nor depleted in acidic residues, which are characteristic of protein quality control degrons [65–67]. Additionally, since the region near the C-terminus does not contain any known C-degrons [68–71], deleting these residues should not lead to increased abundance by removing a C-degron. However, the C-terminus of MLH1 contains an extremely conserved FERC motif, which is suggested to have important regulatory and activity functions [72–76]. Therefore, we hypothesize that truncating the C-terminus stabilizes the protein and creates additional space around the canonical interface, thereby enhancing binding with PMS2, while potentially affecting other properties of MLH1 function mediated by the FERC motif. In general, our experimental abundance and interaction effects are in line with clinical variant classification, as well as with thermodynamic stability predictions and evolutionary conservation. Some variants, however, behave like the wild-type in both the abundance and interaction assays although they were predicted to have minimal impact on protein stability ($\Delta\Delta G \sim 0$) but to be extremely rare or absent from the family of MLH1 homologs ($\Delta\Delta E < -3$). These variants could

be in positions that are critical for other functions of the C-terminal domain of MLH1, such as its interaction with EXO1, which occurs via a different binding site than its interaction with PMS2 [77].

In conclusion, our data suggests that the abundance of MLH1 and its interaction with PMS2 are closely related, with impaired interaction often caused by reduced cellular abundance. We identify detrimental mutations in the canonical interface with PMS2 and uncover a potential distal binding site between MLH1 and PMS2. Our abundance and interaction maps may aid in interpreting clinically observed MLH1 variants and enhance our understanding of their effects in Lynch syndrome.

Materials and Methods

Plasmids and cloning

The DNA sequence of human wild-type MLH1 (UniProt ID: P40692) and human wild-type PMS2 (UniProt ID: P54278) were codon-optimized for yeast expression and cloned into pDONR221 (Genscript). Missense variants were created by Genscript. For the Y2H assay, entry clones were cloned into pDEST22 (prey) or pDEST32 (bait) from the ProQuest Two-Hybrid System (Invitrogen) using Gateway cloning (Invitrogen). For the DHFR-PCA, entry clones were cloned into pDEST-DHFR-PCA using Gateway cloning (Invitrogen).

Yeast strains and media

The Y2H assay was performed in the MaV203 yeast strain from the ProQuest Two-Hybrid System (Invitrogen) and the DHFR-PCA was performed in the BY4741 wild-type yeast strain. Single variant transformations were done as described in [78]. Yeast cells were grown in yeast extract, peptone, dextrose (YPD) medium (2% glucose, 2% tryptone, 1% yeast extract) and in synthetic complete (SC) medium (2% glucose, 0.67% yeast nitrogen base without amino acids (Sigma), 0.2% synthetic drop-out supplement (Sigma)). For the Y2H assay, SC medium without histidine was prepared with 20 mM 3-amino-1,2,4-triazole (3-AT) (Sigma-Aldrich), unless otherwise specified. For the DHFR-PCA yeast growth assays, SC medium without uracil was prepared using drop-out supplement. For the DHFR-PCA library screen, SC medium without uracil was prepared using 76 mg/L histidine, 380 mg/L leucine, 76 mg/L methionine. Selection medium for the DHFR-PCA was prepared using 200 µM methotrexate (MTX) (Sigma-Aldrich) and 1 mM sulfanilamide (Sigma-Aldrich). Control medium for the DHFR-PCA was prepared using a corresponding volume of DMSO. Solid media was prepared using 2% agar.

Yeast growth assays

For growth assays on solid media, cultures were grown overnight (170 rpm, 30 °C) to exponential phase. The cultures were harvested and washed in sterile water (3000 rpm, 5 minutes, room temperature) and the OD_{600nm} was adjusted to 0.4. Then, cultures were used for five-fold dilution series in sterile water and 5 µL of each dilution was spotted onto agar plates. The plates were briefly air-dried before they were incubated at 30 °C for 2-3 days.

Library design and cloning

Full-length human MLH1 was divided into seven tiles of 28, 40 or 42 residues. The residues included in each tile were: tile 1: 487-526, tile 2: 527-568, tile 3: 569-596, tile 4: 597-636, tile 5: 637-676, tile 6: 677-716 and tile 7: 717-756. For each tile, the library was synthesized and cloned into pDONR221 by Twist Bioscience. The libraries comprised all possible single amino acid substitutions at each position as well as the wild-type sequence and a synonymous wild-type mutation at each position. Tile 7 also included a nonsense mutation at each position. Mutagenesis of 15 positions and a total of 307 variants failed during library preparation by Twist Bioscience. The final libraries comprised 4839 out of 5170 (94 %) designed possible single substitution variants and nonsense variants (19 substitutions/per residue*270 residues + 40 nonsense variants). From this point forward, libraries in each tile were handled individually. Entry libraries were cloned into appropriate destination vectors using Gateway cloning (Invitrogen). Briefly, LR reactions were prepared with 243 ng (for the Y2H assay) or 260 ng (for the DHFR-PCA) pDONR221-library, 450 ng pDEST22 (for the Y2H assay) or 450 ng pDEST-DHFR-PCA (for the DHFR-PCA), 6 µL Gateway LR Clonase II enzyme mix (ThermoFisher) and TE buffer to 30 µL. The LR reactions were incubated overnight at room temperature and the following day, the reactions were stopped by adding 3 µL proteinase K (10 minutes, 37 °C). The cloned libraries were electroporated into NEB 10-beta electrocompetent *E. coli* cells (New England Biolabs) using 4 µL LR reaction and 100 µL cells at 1.8 kV. Cells were recovered in 3.9 mL NEB 10-beta stable outgrowth medium for 1 hour (250 rpm, 37 °C). Then, cells were transferred to 36 mL LB medium and 4 µL was plated on LB medium with ampicillin and incubated overnight (37 °C) for estimating the transformation efficiency. The remaining cells were plated on large BioAssay plates (500 cm^2) containing LB medium with ampicillin and incubated overnight (37 °C). For each tile, the number of single colonies exceeded the expected number of variants by at least 100-fold. The following day, cells were scraped off the plates with sterile water and library DNA was isolated and purified using the NucleoBond Xtra Midi kit (Macherey–Nagel).

Library transformation and selection

The cloned MLH1 libraries in each tile were transformed and plated for selection separately. The libraries cloned into pDEST22 were transformed into the MaV203 yeast strain with pDEST32-PMS2 to perform the Y2H assay. The libraries cloned into pDEST-DHFR-PCA were transformed into the BY4741 wild-type yeast strain to perform the DHFR-PCA. Transformations were done using 30× scale-up as described in [79]. For the Y2H assay, the

MaV203 yeast strain with pDEST32-PMS2 was grown overnight (170 rpm, 30 °C) in SC-leucine medium. For the DHFR-PCA, the BY4741 wild-type yeast strain was grown overnight (170 rpm, 30 °C) in YPD medium. Upon reaching late-exponential phase, the cultures were diluted in at least 150 mL SC-leucine medium (for the Y2H assay) or YPD medium (for the DHFR-PCA) to an OD_{600nm} of 0.3 and incubated (170 rpm, 30 °C) until an OD_{600nm} of 1.2 was reached. The cells were harvested and washed in sterile water (3000 rpm, 5 minutes, room temperature). The cell pellets were resuspended in a transformation mix and incubated in a water bath (40 minutes, 42 °C). The transformation mixed contained: 7.2 mL 50% PEG-3350 (Sigma), 1.08 mL 1 M LiAc (Sigma), 300 µL 10 mg/mL freshly denatured carrier DNA (Sigma), 30 µg cloned library plasmid DNA and sterile water to 10.8 mL. Then, the cells were harvested (3000 rpm, 5 minutes, room temperature) and the transformation mix was discarded. The cell pellets were resuspended in 30 mL sterile water and 5 µL and 10 µL were plated on SC-leucine-tryptophan medium (for the Y2H assay) or SC-uracil medium (for the DHFR-PCA) and incubated for two days (30 °C) to evaluate the efficiency of the transformations. The remaining cells were diluted in SC-leucine-tryptophan medium (for the Y2H assay) or SC-uracil medium (for the DHFR-PCA) to an OD_{600nm} of 0.2 and incubated for two days (170 rpm, 30 °C). For each tile, for both the DHFR-PCA and Y2H assay, every variant was represented at least 100 times. After two days, the transformation cultures reached saturation. For the Y2H assay, 2×4.5 OD_{600nm} units were harvested (17,000 g, 1 minute, room temperature) in triplicates, washed in sterile water and resuspended in 600 µL sterile water. Then, 300 µL was plated on large BioAssay plates (500 cm^2) containing SC-leucine-tryptophan medium to serve as the control condition. The remaining 300 µL was plated on large BioAssay plates (500 cm^2) containing SC-leucine-tryptophan-histidine medium with 20 mM 3-amino-1,2,4-triazole (3-AT) to serve as the selection condition. The plates were air-dried and incubated at 30 °C for two days. For the DHFR-PCA, 2×22.5 OD_{600nm} units were harvested (17,000 g, 1 minute, room temperature) in triplicates, washed in sterile water and resuspended in 600 µL sterile water. Then, 300 µL was plated on large BioAssay plates (500 cm^2) containing SC+histidine+leucine+methionine medium to serve as the control condition. The remaining 300 µL was plated on large BioAssay plates (500 cm^2) containing SC+histidine+leucine+methionine medium with 200 µM MTX and 1 mM sulfanilamide to serve as the selection condition. The plates were air-dried and incubated at 30 °C for three days. Following the incubation, yeast cells were scraped off the plates using 30 mL sterile water and 9 OD_{600nm} units from each plate was harvested (17,000 g, 1 minute, room temperature) and

used for plasmid purification. Library plasmid DNA was isolated from yeast cells using the ChargeSwitch Plasmid Yeast Mini kit (Invitrogen).

Amplicon preparation and library sequencing

Amplicons for each tile were prepared via two rounds of PCR, with the product cleaned-up after each reaction. For the first PCR, 50 µL reactions were prepared by mixing 25 µL of 2× Phusion High-Fidelity PCR Master Mix (New England Biolabs), 5 ng of purified library plasmid DNA, 2.5 µL of 10 µM forward and reverse tile-specific primers with Illumina adapter sequences, and nuclease-free water to reach a total volume of 50 µL. The primer sequences and annealing temperatures are listed in the supplementary material [Supplementary File 1]. The reactions were subjected to the following PCR program: 98 °C for 30 seconds, followed by 8 cycles of 98 °C for 10 seconds, 57-64 °C for 30 seconds, 72 °C for 20 seconds, followed by 72 °C for 2 minutes and 4 °C hold. The product from the first PCR was cleaned-up using Ampure XP beads (Beckman Coulter). Briefly, 15 µL of the PCR product were thoroughly mixed with 14.25 µL Ampure XP beads in 1.5 mL Eppendorf tubes and incubated at room temperature for 5 minutes. Following the incubation, the tubes were placed on a magnetic stand and the supernatant was carefully removed before the beads were washed twice with 200 µL 70% ethanol. The beads were air-dried at room temperature for 15 minutes to allow residual ethanol to evaporate. Finally, the cleaned-up PCR product was eluted from the beads with nuclease-free water and mixed thoroughly. The tubes were placed on a magnetic stand and the cleared supernatant was transferred to a fresh 1.5 mL Eppendorf tube. Then, 50 µL reactions were prepared for the second PCR by mixing 25 µL of 2× Phusion High-Fidelity PCR Master Mix (New England Biolabs), 15 µL of cleaned-up PCR product from the first PCR and 10 µL Nextera DNA CD Indexes (96-well format from Illumina) for dual indexing. The reactions were subjected to the following PCR program: 98 °C for 30 seconds, followed by 12 cycles of 98 °C for 10 seconds, 62 °C for 30 seconds, 72 °C for 20 seconds, followed by 72 °C for 2 minutes and 4 °C hold. The product from the second PCR was cleaned-up as described for the first PCR, using 11.25 µL Ampure XP beads. Finally, the concentration of the amplicons was measured using the Qubit 2.0 Fluorometer (Invitrogen) with the Qubit dsDNA HS Assay kit (Thermo Fisher Scientific) and the integrity was assessed using the 2100 Bioanalyzer (Agilent Technologies) with the High Sensitivity DNA kit. The amplicons were volumetrically pooled and diluted before they were subjected to pair-end next-generation sequencing using the Illumina NextSeq 550 System with the Mid Output v2.5 300 cycle kit (Illumina).

Analysis of sequencing data

FASTQ files with read 1 and read 2 were downloaded from BaseSpace and sequences from the four lanes were merged. The quality and length of sequences in the merged read 1 and read 2 FASTQ files were assessed using FastQC [80]. Then, Trimmomatic [81] paired-end mode was used to obtain sequences of 151 base pairs using the following flags: MINLEN:151 and CROP:151. The FASTQ files with trimmed sequences were used as input to Enrich2 [47] to count reads and calculate a score for each variant. Enrich2 calculated log ratios and standard errors for each variant based on three replicates using the control condition as time point 1 and the selection condition as time point 2. The scores were calculated by normalization to synonymous wild-type variants. Enrich2 was run using the overlap mode with default parameters, but with a minimum and average quality of 1, maximum N's of 0, maximum mismatches of 0, and 'remove unresolvable overlaps' and 'overlap only' set to TRUE. The start and end were appropriately indicated for each tile. The wild-type sequence was included with the correct offset for each tile. For the DHFR-PCA, the scores appeared clearly bimodal with a wild-type-like peak centered around 0 and a peak of unstable variants with negative scores (**Supplementary Fig. 4B**). However, the low-abundance peak displayed varying scores between tiles. Hence, to put all tiles on a similar scale, the DHFR-PCA scores were rescaled per tile by dividing all scores with the score of the low-abundance peak, giving scores ranging from -1 to 1, with wild-type centered at 0. For the Y2H assay, the score distributions did not appear bimodal, but instead all tiles had a sharp wild-type-like peak centered around 0 and few loss- or gain-of-interaction variants, and therefore, we omitted to rescale the scores (**Supplementary Fig. 4C**). The heatmaps were produced in R using the packages ComplexHeatmap [82] and circlize [83].

Modeling and structural analysis

The C-terminal MutLα complex was predicted using AlphaFold2-Multimer. AlphaFold2-Multimer was run using ColabFold [84]. The C-terminal domain of MLH1 (UniProt ID: P40692) included residue 487-756 and the C-terminal domain of PMS2 (UniProt ID: P54278) included residue 611-862. The N-terminal domains of MLH1 and PMS2 shown in **Fig. 1A** are PDB: 4P7A [85] and 1H7S [86], respectively.

The surface hydrophobicity of the C-terminal domain of MLH1 was assessed using the YRB script [60] in PyMOL with the AlphaFold2-predicted structure. We used the predicted structure of the C-terminal domain of MLH1 due to the homomeric nature of the of solved structure (PDB: 3RBN), which rendered it unsuitable for this analysis.

Thermodynamic stability predictions

Rosetta with the Cartesian ΔΔG protocol [48] (GitHub SHA1 99d33ec59ce9fcecc5e4f3800c778a54afdf8504) was used on the crystal structure of the C-terminal domain of MLH1 (PDB: 3RBN) to predict the changes in thermodynamic stability of MLH1 variants. The MLH1 structures were prepared and relaxed and inputted for ΔΔG calculations using an in-house pipeline (https://github.com/KULL-Centre/PRISM/tree/main/software/rosetta_ddG_pipeline, v0.2.1). The change in folding stability was calculated by subtracting the wild-type ΔG value from the variant ΔG value. The ΔΔG values in Rosetta Energy Units were divided by 2.9 to convert them to kcal/mol [48].

Evolutionary conservation predictions

The evolutionary conservation ΔΔE score was calculated using GEMME [49]. The first isoform of MLH1 (UniProt: P40692-1) was input into HHblits [87] to build an MSA of MLH1 homologs using an E-value threshold of 10^{-10}. The resulting MSA was refined by first including only positions present in the wild-type MLH1 sequence and then by excluding sequences with more than 50% gaps. This process resulted in a final MSA containing 683 MLH1 homologs, which was input into GEMME to estimate the evolutionary distance of the MLH1 variants from the wild-type MLH1 sequence.

Acknowledgements

We acknowledge the use of the sequencing and computing core facilities at the Department of Biology, University of Copenhagen. We thank Aleksandra Panfilova for help with the preliminary processing of sequencing data, Vasileios Voutsinos for assistance with Illumina sequencing and Matteo Cagiada for running Rosetta and GEMME predictions. pDEST-DHFR-PCA was a gift from Professor Rasmus Hartmann-Petersen (University of Copenhagen). Parts of Fig. 1 were created using BioRender.com.

Competing interests

The authors declare no competing interests.

Supplemental files

This article includes the following supplemental information.

- Supplemental figures (SupplementalFigures.pdf).
- Supplemental dataset (SupplementalFile1.xlsx).

Data and code availability

All data generated are included in the figures and supplemental files. The code is available at GitHub (https://github.com/KULL-Centre/_2024_Larsen-Ledet_MLH1).

Author contributions

S.L.-L performed the experiments. S.L.-L and A.S. analyzed the data and conceived the study. S.L.-L wrote the paper.

Funding

The present work was supported by grants from the Lundbeck Foundation (R209-2015-3283) and the Novo Nordisk Foundation challenge program PRISM (NNF18OC0033950). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Anfinsen CB, Haber E, Sela M, White FH. THE KINETICS OF FORMATION OF NATIVE RIBONUCLEASE DURING OXIDATION OF THE REDUCED POLYPEPTIDE CHAIN. Proceedings of the National Academy of Sciences. 1961 Sep;47(9):1309–14.

2. Stein A, Fowler DM, Hartmann-Petersen R, Lindorff-Larsen K. Biophysical and Mechanistic Models for Disease-Causing Protein Variants. Trends Biochem Sci. 2019 Jul;44(7):575–88.

3. Høie MH, Cagiada M, Beck Frederiksen AH, Stein A, Lindorff-Larsen K. Predicting and interpreting large-scale mutagenesis data using analyses of protein stability and conservation. Cell Rep. 2022 Jan;38(2):110207.

4. Hernández-Ramírez LC, Martucci F, Morgan RML, Trivellin G, Tilley D, Ramos-Guajardo N, et al. Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense *AIP* Mutations. J Clin Endocrinol Metab. 2016 Aug;101(8):3144–54.

5. Taipale M. Disruption of protein function by pathogenic mutations: common and uncommon mechanisms. Biochemistry and Cell Biology. 2019 Feb;97(1):46–57.

6. Blaabjerg LM, Kassem MM, Good LL, Jonsson N, Cagiada M, Johansson KE, et al. Rapid protein stability prediction using deep learning representations. Elife. 2023 May 15;12.

7. Scheller R, Stein A, Nielsen S V., Marin FI, Gerdes A, Marco M, et al. Toward mechanistic models for genotype–phenotype correlations in phenylketonuria using protein stability calculations. Hum Mutat. 2019 Apr 25;40(4):444–57.

8. Yue P, Li Z, Moult J. Loss of Protein Structure Stability as a Major Causative Factor in Monogenic Disease. J Mol Biol. 2005 Oct;353(2):459–73.

9. Cagiada M, Johansson KE, Valanciute A, Nielsen S V, Hartmann-Petersen R, Yang JJ, et al. Understanding the Origins of Loss of Protein Function by Analyzing the Effects of Thousands of Variants on Activity and Abundance. Mol Biol Evol. 2021 Jul 29;38(8):3235–46.

10. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, et al. A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome. Cell. 2005 Sep;122(6):957–68.

11. Burke DF, Bryant P, Barrio-Hernandez I, Memon D, Pozzati G, Shenoy A, et al. Towards a structurally resolved human protein interaction network. Nat Struct Mol Biol. 2023 Feb 23;30(2):216–25.

12. Luck K, Kim DK, Lambourne L, Spirohn K, Begg BE, Bian W, et al. A reference map of the human binary protein interactome. Nature. 2020 Apr 16;580(7803):402–8.

13. Schreiber G. Protein–Protein Interaction Interfaces and their Functional Implications. In: Protein – Protein Interaction Regulators. The Royal Society of Chemistry; 2020. p. 1–24.

14. Mintseris J, Weng Z. Structure, function, and evolution of transient and obligate protein–protein interactions. Proceedings of the National Academy of Sciences. 2005 Aug 2;102(31):10930–5.

15. Perkins JR, Diboun I, Dessailly BH, Lees JG, Orengo C. Transient Protein-Protein Interactions: Structural, Functional, and Network Properties. Structure. 2010 Oct;18(10):1233–43.

16. Mintseris J, Weng Z. Structure, function, and evolution of transient and obligate protein–protein interactions. Proceedings of the National Academy of Sciences. 2005 Aug 2;102(31):10930–5.

17. Ivarsson Y, Jemth P. Affinity and specificity of motif-based protein–protein interactions. Curr Opin Struct Biol. 2019 Feb;54:26–33.

18. David A, Razali R, Wass MN, Sternberg MJE. Protein-protein interaction sites are hot spots for disease-associated nonsynonymous SNPs. Hum Mutat. 2012 Feb;33(2):359–63.

19. David A, Sternberg MJE. The Contribution of Missense Mutations in Core and Rim Residues of Protein–Protein Interfaces to Human Disease. J Mol Biol. 2015 Aug;427(17):2886–98.

20. Xiong D, Lee D, Li L, Zhao Q, Yu H. Implications of disease-related mutations at protein–protein interfaces. Curr Opin Struct Biol. 2022 Feb;72:219–25.

21. Cheng F, Zhao J, Wang Y, Lu W, Liu Z, Zhou Y, et al. Comprehensive characterization of protein–protein interactions perturbed by disease mutations. Nat Genet. 2021 Mar 8;53(3):342–53.

22. Sahni N, Yi S, Taipale M, Fuxman Bass JI, Coulombe-Huntington J, Yang F, et al. Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders. Cell. 2015 Apr;161(3):647–60.

23. Zhong Q, Simonis N, Li Q, Charloteaux B, Heuze F, Klitgord N, et al. Edgetic perturbation models of human inherited disorders. Mol Syst Biol. 2009 Jan 3;5(1).

24. Sahni N, Yi S, Zhong Q, Jailkhani N, Charloteaux B, Cusick ME, et al. Edgotype: a fundamental link between genotype and phenotype. Curr Opin Genet Dev. 2013 Dec;23(6):649–57.

25. Mitchell AL, Attwood TK, Babbitt PC, Blum M, Bork P, Bridge A, et al. InterPro in 2019: improving coverage, classification and access to protein sequence annotations. Nucleic Acids Res. 2019 Jan 8;47(D1):D351–60.

26. Guerrette S, Acharya S, Fishel R. The Interaction of the Human MutL Homologues in Hereditary Nonpolyposis Colon Cancer. Journal of Biological Chemistry. 1999 Mar;274(10):6336–41.

27. Pećina-Šlaus N, Kafka A, Salamon I, Bukovac A. Mismatch Repair Pathway, Genome Stability and Cancer. Front Mol Biosci. 2020 Jun 26;7.

28. Jun S, Kim TG, Ban C. DNA mismatch repair system. FEBS J. 2006 Apr 31;273(8):1609–19.

29. Momma T, Gonda K, Akama Y, Endo E, Ujiie D, Fujita S, et al. MLH1 germline mutation associated with Lynch syndrome in a family followed for more than 45 years. BMC Med Genet. 2019 Dec 2;20(1):67.

30. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer. Nature. 1994 Mar;368(6468):258–61.

31. Plazzer JP, Sijmons RH, Woods MO, Peltomäki P, Thompson B, Den Dunnen JT, et al. The InSiGHT database: utilizing 100 years of insights into Lynch Syndrome. Fam Cancer. 2013 Jun 27;12(2):175–80.

32. Abildgaard AB, Stein A, Nielsen S V, Schultz-Knudsen K, Papaleo E, Shrikhande A, et al. Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome. Elife. 2019 Nov 7;8.

33. Abildgaard AB, Nielsen S V., Bernstein I, Stein A, Lindorff-Larsen K, Hartmann-Petersen R. Lynch syndrome, molecular mechanisms and variant classification. Br J Cancer. 2023 Mar 23;128(5):726–34.

34. Peltomäki P. Update on Lynch syndrome genomics. Fam Cancer. 2016 Jul 12;15(3):385–93.

35. Pérez-Palma E, Gramm M, Nürnberg P, May P, Lal D. Simple ClinVar: an interactive web server to explore and retrieve gene and disease variants aggregated in ClinVar database. Nucleic Acids Res. 2019 Jul 2;47(W1):W99–105.

36. Gueneau E, Dherin C, Legrand P, Tellier-Lebegue C, Gilquin B, Bonnesoeur P, et al. Structure of the MutLα C-terminal domain reveals how Mlh1 contributes to Pms1 endonuclease site. Nat Struct Mol Biol. 2013 Apr 24;20(4):461–8.

37. Remy I, Michnick SW. Clonal selection and *in vivo* quantitation of protein interactions with protein-fragment complementation assays. Proceedings of the National Academy of Sciences. 1999 May 11;96(10):5394–9.

38. Tarassov K, Messier V, Landry CR, Radinovic S, Molina MMS, Shames I, et al. An in Vivo Map of the Yeast Protein Interactome. Science (1979). 2008 Jun 13;320(5882):1465–70.

39. Levy ED, Kowarzyk J, Michnick SW. High-Resolution Mapping of Protein Concentration Reveals Principles of Proteome Architecture and Adaptation. Cell Rep. 2014 May;7(4):1333–40.

40. Faure AJ, Domingo J, Schmiedel JM, Hidalgo-Carcedo C, Diss G, Lehner B. Mapping the energetic and allosteric landscapes of protein binding domains. Nature. 2022 Apr 7;604(7904):175–83.

41. Fields S, Song O kyu. A novel genetic system to detect protein–protein interactions. Nature. 1989 Jul;340(6230):245–6.

42. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018 Jan 4;46(D1):D1062–7.

43. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020 May 28;581(7809):434–43.

44. Guerrette S, Acharya S, Fishel R. The Interaction of the Human MutL Homologues in Hereditary Nonpolyposis Colon Cancer. Journal of Biological Chemistry. 1999 Mar;274(10):6336–41.

45. Rath A, Radecki AA, Rahman K, Gilmore RB, Hudson JR, Cenci M, et al. A calibrated cell-based functional assay to aid classification of *MLH1* DNA mismatch repair gene variants. Hum Mutat. 2022 Dec 12;43(12):2295–307.

46. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C. Functional Analysis of Human *MLH1* Variants Using Yeast and *In vitro* Mismatch Repair Assays. Cancer Res. 2007 May 15;67(10):4595–604.

47. Rubin AF, Gelman H, Lucas N, Bajjalieh SM, Papenfuss AT, Speed TP, et al. A statistical framework for analyzing deep mutational scanning data. Genome Biol. 2017 Dec 7;18(1):150.

48. Park H, Bradley P, Greisen P, Liu Y, Mulligan VK, Kim DE, et al. Simultaneous Optimization of Biomolecular Energy Functions on Features from Small Molecules and Macromolecules. J Chem Theory Comput. 2016 Dec 13;12(12):6201–12.

49. Laine E, Karami Y, Carbone A. GEMME: A Simple and Fast Global Epistatic Model Predicting Mutational Effects. Mol Biol Evol. 2019 Nov 1;36(11):2604–19.

50. Kansikas M, Kariola R, Nyström M. Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants. Hum Mutat. 2011 Jan;32(1):107–15.

51. Dominguez-Valentin M, Plazzer JP, Sampson JR, Engel C, Aretz S, Jenkins MA, et al. No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. J Clin Med. 2021 Jun 28;10(13):2856.

52. Drost M, Tiersma Y, Thompson BA, Frederiksen JH, Keijzers G, Glubb D, et al. A functional assay–based procedure to classify mismatch repair gene variants in Lynch syndrome. Genetics in Medicine. 2019 Jul;21(7):1486–96.

53. Cravo M. Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing. Gut. 2002 Mar 1;50(3):405–12.

54. Singh P, Fragoza R, Blengini CS, Tran TN, Pannafino G, Al-Sweel N, et al. Human MLH1/3 variants causing aneuploidy, pregnancy loss, and premature reproductive aging. Nat Commun. 2021 Aug 18;12(1):5005.

55. Clausen L, Voutsinos V, Cagiada M, Johansson KE, Grønbæk-Thygesen M, Nariya S, et al. A mutational atlas for Parkin proteostasis. Nat Commun. 2024 Feb 20;15(1):1541.

56. Grønbæk-Thygesen M, Voutsinos V, Johansson KE, Schulze TK, Cagiada M, Pedersen L, et al. Deep mutational scanning reveals a correlation between degradation and toxicity of thousands of aspartoacylase variants. Nat Commun. 2024 May 13;15(1):4026.

57. Abildgaard AB, Stein A, Nielsen S V, Schultz-Knudsen K, Papaleo E, Shrikhande A, et al. Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome. Elife. 2019 Nov 7;8.

58. Davey NE, Van Roey K, Weatheritt RJ, Toedt G, Uyar B, Altenberg B, et al. Attributes of short linear motifs. Mol BioSyst. 2012;8(1):268–81.

59. Teilum K, Olsen JG, Kragelund BB. On the specificity of protein–protein interactions in the context of disorder. Biochemical Journal. 2021 Jun 11;478(11):2035–50.

60. Hagemans D, van Belzen IAEM, Morán Luengo T, Rüdiger SGD. A script to highlight hydrophobicity and charge on protein surfaces. Front Mol Biosci. 2015 Oct 13;2.

61. Leong V, Lorenowicz J, Kozij N, Guarné A. Nuclear import of human MLH1, PMS2, and MutLα: Redundancy is the key. Mol Carcinog. 2009 Aug 15;48(8):742–50.

62. de Barros AC, Takeda AAS, Dreyer TR, Velazquez-Campoy A, Kobe B, Fontes MRM. DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus by a classical nuclear import pathway. Biochimie. 2018 Mar;146:87–96.

63. Brieger A, Plotz G, Raedle J, Weber N, Baum W, Caspary WF, et al. Characterization of the nuclear import of human MutLα. Mol Carcinog. 2005 May 7;43(1):51–8.

64. Wu X, Platt JL, Cascalho M. Dimerization of MLH1 and PMS2 Limits Nuclear Localization of MutLα. Mol Cell Biol. 2003 May 1;23(9):3320–8.

65. Mashahreh B, Armony S, Johansson KE, Chappleboim A, Friedman N, Gardner RG, et al. Conserved degronome features governing quality control associated proteolysis. Nat Commun. 2022 Dec 8;13(1):7588.

66. Abildgaard AB, Voutsinos V, Petersen SD, Larsen FB, Kampmeyer C, Johansson KE, et al. HSP70-binding motifs function as protein quality control degrons. Cellular and Molecular Life Sciences. 2023 Jan 7;80(1):32.

67. Johansson KE, Mashahreh B, Hartmann-Petersen R, Ravid T, Lindorff-Larsen K. Prediction of Quality-control Degradation Signals in Yeast Proteins. J Mol Biol. 2023 Jan;435(2):167915.

68. Timms RT, Mena EL, Leng Y, Li MZ, Tchasovnikarova IA, Koren I, et al. Defining E3 ligase–substrate relationships through multiplex CRISPR screening. Nat Cell Biol. 2023 Oct 21;25(10):1535–45.

69. Kong KYE, Shankar S, Rühle F, Khmelinskii A. Orphan quality control by an SCF ubiquitin ligase directed to pervasive C-degrons. Nat Commun. 2023 Dec 15;14(1):8363.

70. Koren I, Timms RT, Kula T, Xu Q, Li MZ, Elledge SJ. The Eukaryotic Proteome Is Shaped by E3 Ubiquitin Ligases Targeting C-Terminal Degrons. Cell. 2018 Jun;173(7):1622-1635.e14.

71. Timms RT, Koren I. Tying up loose ends: the N-degron and C-degron pathways of protein degradation. Biochem Soc Trans. 2020 Aug 28;48(4):1557–67.

72. Reyes GX, Schmidt TT, Kolodner RD, Hombauer H. New insights into the mechanism of DNA mismatch repair. Chromosoma. 2015 Dec 11;124(4):443–62.

73. Wu T, Yang S, Fang J, Ye Y, Zhang Y, Gao J, et al. *MutL homolog 1* participates in interference-sensitive meiotic crossover formation in soybean. Plant Physiol. 2024 Mar 16;

74. Smith CE, Mendillo ML, Bowen N, Hombauer H, Campbell CS, Desai A, et al. Dominant Mutations in S. cerevisiae PMS1 Identify the Mlh1-Pms1 Endonuclease Active Site and an Exonuclease 1-Independent Mismatch Repair Pathway. PLoS Genet. 2013 Oct 31;9(10):e1003869.

75. Gueneau E, Dherin C, Legrand P, Tellier-Lebegue C, Gilquin B, Bonnesoeur P, et al. Structure of the MutLα C-terminal domain reveals how Mlh1 contributes to Pms1 endonuclease site. Nat Struct Mol Biol. 2013 Apr 24;20(4):461–8.

76. Putnam CD, Kolodner RD. Insights into DNA cleavage by MutL homologs from analysis of conserved motifs in eukaryotic Mlh1. BioEssays. 2023 Jul 9;

77. Dherin C, Gueneau E, Francin M, Nunez M, Miron S, Liberti SE, et al. Characterization of a Highly Conserved Binding Site of Mlh1 Required for Exonuclease I-Dependent Mismatch Repair. Mol Cell Biol. 2009 Feb 1;29(3):907–18.

78. Gietz RD, Schiestl RH. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc. 2007 Jan 31;2(1):31–4.

79. Gietz RD, Schiestl RH. Large-scale high-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc. 2007 Jan 31;2(1):38–41.

80. Andrews S. FastQC: A Quality Control Tool for High Throughput Sequence Data [Online]. Available online at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. 2010;

81. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014 Aug 1;30(15):2114–20.

82. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016 Sep 15;32(18):2847–9.

83. Gu Z, Gu L, Eils R, Schlesner M, Brors B. *circlize* implements and enhances circular visualization in R. Bioinformatics. 2014 Oct 1;30(19):2811–2.

84. Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods. 2022 Jun 30;19(6):679–82.

85. Wu H, Zeng H, Lam R, Tempel W, Kerr ID, Min J. Structure of the human MLH1 N-terminus: implications for predisposition to Lynch syndrome. Acta Crystallogr F Struct Biol Commun. 2015 Aug 1;71(8):981–5.

86. Guarne A. Structure and function of the N-terminal 40 kDa fragment of human PMS2: a monomeric GHL ATPase. EMBO J. 2001 Oct 1;20(19):5521–31.

87. Remmert M, Biegert A, Hauser A, Söding J. HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment. Nat Methods. 2012 Feb 25;9(2):173–5.



Fig. 1 – *Yeast-based abundance and interaction assays to measure variant effects in MLH1.* (A) The MutLα complex (MLH1:PMS2) participates in the DNA mismatch repair (MMR) pathway together with several other components to recognize and correct mismatches during DNA replication. MLH1 (purple) and PMS2 (orange) fold into an N-terminal domain (NTD) and a C-terminal domain (CTD), separated by a disordered linker. The two proteins interact through their C-terminal domains. The C-terminal MutLα complex was predicted using AlphaFold2-Multimer, whereas the N-terminal domain of MLH1 is PDB: 4P7A and the N-terminal domain of PMS2 is PDB: 1H7S. The disordered linkers between the domains were hand-drawn for illustrative purposes. (B) Schematic illustration of the dihydrofolate reductase protein-fragment complementation assay (DHFR-PCA) used to measure the cellular abundance of MLH1 variants. (C) Schematic illustration of the yeast two-hybrid (Y2H) assay used to measure the interaction of MLH1 variants with PMS2.


A
Abundance
without MTX
with MTX
vector
WT
Q542L
L550P
S406N
I219V
T117M
Interaction
Prey: MLH1
with histidine
without histidine
Bait: PMS2
B
Entry library
Cloned library
Transformation
Selection
Amplicons
Sequencing
Data analysis
Y2H
DHFR-PCA
with histidine
without histidine
without MTX
with MTX
Abundance
Interaction
C
Abundance
Interaction
L550P
WT
Count
Abundance score
Interaction score

Fig. 2 – *Screening of site-saturation mutagenesis libraries in the C-terminal domain of MLH1.* (A) Small-scale yeast growth assays to test the DHFR-PCA (left) and the Y2H assay (right). Yeast cells expressed either a vector, wild-type MLH1, or the indicated MLH1 variant. For the DHFR-PCA the vector was an empty vector, while for the Y2H assay the vector was the activation domain (AD) expressed without MLH1. For the DHFR-PCA, cells were grown on medium with or without MTX at 30 °C. For the Y2H assay, cells co-expressed PMS2 as bait fused to the DNA binding domain and were grown on medium with or without histidine at 30 °C. Q542L and L550P are in the C-terminal domain, S406N is in the disordered linker, and I219V and T117M are in the N-terminal domain. (B) Overview of the experimental design to screen libraries of MLH1 variants for abundance and interaction with PMS2. (C) Histograms showing the score distributions of MLH1 variants in the DHFR-PCA (left) and the Y2H assay (right). A score of 0 corresponds to the wild-type in both assays, while a negative or positive score indicates reduced or increased abundance or interaction, respectively. As a reference, the abundance and interaction score of the wild-type MLH1 (black) and the L550P variant (red) are highlighted with dashed lines. The abundance scores were rescaled to range from -1 to 1 (see Materials and Methods).


A
Abundance
His
Lys
Arg
Asp
Glu
Cys
Met
Asn
Gln
Ser
Thr
Pro
Ala
Ile
Leu
Val
Phe
Trp
Tyr
Gly
Ter
487 497 507 517 527 537 547 557 567 577 587 597 607 617 627 637 647 657 667 677 687 697 707 717 727 737 747 756
Abundance score
Low abundance
WT abundance
High abundance
Wild-type amino acid
Missing variant
B
PMS2 CTD
MLH1 CTD
756
487
180°
PMS2 CTD
MLH1 CTD
756
487
C
Interaction
His
Lys
Arg
Asp
Glu
Cys
Met
Asn
Gln
Ser
Thr
Pro
Ala
Ile
Leu
Val
Phe
Trp
Tyr
Gly
Ter
487 497 507 517 527 537 547 557 567 577 587 597 607 617 627 637 647 657 667 677 687 697 707 717 727 737 747 756
Interaction score
Weak interaction
WT interaction
Strong interaction
Wild-type amino acid
Missing variant
D
PMS2 CTD
MLH1 CTD
756
487
180°
PMS2 CTD
MLH1 CTD
756
487

Fig. 3 – *MLH1 abundance and interaction heatmaps*. (A) Heatmaps showing the abundance scores of MLH1 variants. The scores range from low abundance (red), through wild-type-like abundance (white), to high abundance (blue). The wild-type residue at each position is marked in yellow, while missing variants are marked in gray. Substitutions that lead to a stop codon (nonsense mutations) are indicted by 'Ter'. The position in the full-length MLH1 protein is shown below the heatmap. A linear representation of the secondary structure of MLH1 is displayed above the heatmap, colored by AlphaFold2 pLDDT as a measure of disorder. (B) The per-position median abundance scores are mapped to the C-terminal domain of MLH1 in the AlphaFold2-Multimer predicted C-terminal MutLα complex. The color scale corresponds to that shown in Fig. 3A. The C-terminal domain of PMS2 is shown in orange. The N- and C-terminus of the C-terminal domain of MLH1 are annotated with the position in the full-length MLH1 protein. (C) Same as in (A), but for interaction scores. (D) Same as in (B), but for interaction scores.


A
B
GEMME ΔΔE
Rosetta ΔΔG
Abundance score
Low abundance
WT abundance
High abundance
Interaction score
Weak interaction
WT interaction
Strong interaction
C
D
Abundance score
Interaction score
gnomAD allele frequency (log)
ClinVar
Benign
Likely benign
Likely pathogenic
Pathogenic
Uncertain significance

Fig. 4 – *Experimental effects correlate with computational predictions and clinical classifications*. (A) Scatter plots showing the correlation between the predicted GEMME ΔΔE score and predicted Rosetta ΔΔG score. A negative ΔΔE score suggests that the variant may not be compatible with MLH1 function as encoded in the sequence family. A positive ΔΔG score suggests that the variant is less stable than the wild-type MLH1. The MLH1 variants are colored by the abundance score and the color scale corresponds to that shown in Fig. 3A. (B) Same as in (A), but for interaction scores. (C) Scatter plots showing the correlation between the abundance score and the gnomAD allele frequency (log scale). The MLH1 variants are colored based on their classification in ClinVar as either benign (dark green), likely benign (light green), likely pathogenic (yellow), pathogenic (red) or uncertain significance (gray). Variants observed in patients but not in gnomAD are indicated to the left of the dashed lines on the x-axis. These variants were retrieved from Simple ClinVar [35] (accessed July 25, 2024). (D) Same as in (C), but for interaction scores.


A
GEMME ΔΔE
Rosetta ΔΔG
Abundance score
Low abundance
WT abundance
High abundance
B
GEMME ΔΔE
Rosetta ΔΔG
Interaction score
Weak interaction
WT interaction
Strong interaction
C
Abundance score
gnomAD allele frequency (log)
ClinVar
Benign
Likely benign
Likely pathogenic
Pathogenic
Uncertain significance
D
Interaction score
gnomAD allele frequency (log)
ClinVar
Benign
Likely benign
Likely pathogenic
Pathogenic
Uncertain significance


A
Abundance
His
Lys
Arg
Asp
Glu
Cys
Met
Asn
Gln
Ser
Thr
Pro
Ala
Ile
Leu
Val
Phe
Trp
Tyr
Gly
Ter
487 497 507 517 527 537 547 557 567 577 587 597 607 617 627 637 647 657 667 677 687 697 707 717 727 737 747 756
Abundance score
Low abundance
WT abundance
High abundance
Wild−type amino acid
Missing variant
B
PMS2 CTD
MLH1 CTD
756
487
180°
PMS2 CTD
MLH1 CTD
756
487
C
Interaction
His
Lys
Arg
Asp
Glu
Cys
Met
Asn
Gln
Ser
Thr
Pro
Ala
Ile
Leu
Val
Phe
Trp
Tyr
Gly
Ter
487 497 507 517 527 537 547 557 567 577 587 597 607 617 627 637 647 657 667 677 687 697 707 717 727 737 747 756
Interaction score
Weak interaction
WT interaction
Strong interaction
Wild−type amino acid
Missing variant
D
PMS2 CTD
MLH1 CTD
756
487
180°
PMS2 CTD
MLH1 CTD
756
487


A
Abundance
without MTX
with MTX
vector
WT
Q542L
L550P
S406N
I219V
T117M
Interaction
Prey: MLH1
with histidine
without histidine
Bait: PMS2
B
Entry library
Cloned library
Transformation
Selection
Amplicons
Sequencing
Data analysis
Y2H
DHFR-PCA
with histidine
without histidine
without MTX
with MTX
Abundance
Interaction


C
Abundance
Interaction
L550P
WT
Count
Abundance score
Interaction score


A
DNA mistmach repair pathway
5'
3'
MutLα complex
MLH1
PMS2
5'
3'
PMS2 CTD
MLH1 CTD
PMS2 NTD
MLH1 NTD
B
Abundance
F[1,2]
MLH1
F[3]
High abundance
DHFR
MLH1
Low abundance
F[1,2]
without MTX
with MTX
High abundance:
Low abundance:
C
Interaction
MLH1
PMS2
AD
DBD
HIS3
with histidine
without histidine
Strong interaction:
Weak interaction: